Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Screening and Preliminary Biochemical and Biological Studies of [RuCl(p-cymene)(N,N-bis(diphenylphosphino)-isopropylamine)][BF4] in Breast Cancer Models.

Corrales Sánchez V, Nieto-Jiménez C, Castro-Osma JA, de Andrés F, Pacheco-Liñán PJ, Bravo I, Rodríguez Fariñas N, Niza E, Domínguez-Jurado E, Lara-Sánchez A, Ríos Á, Gómez Juárez M, Montero JC, Pandiella A, Shafir A, Alonso-Moreno C, Ocaña A.

ACS Omega. 2019 Aug 1;4(8):13005-13014. doi: 10.1021/acsomega.9b00296. eCollection 2019 Aug 20.

2.

Transcriptome evolution from breast epithelial cells to basal-like tumors.

Santpere G, Alcaráz-Sanabria A, Corrales-Sánchez V, Pandiella A, Győrffy B, Ocaña A.

Oncotarget. 2017 Dec 8;9(1):453-463. doi: 10.18632/oncotarget.23065. eCollection 2018 Jan 2.

3.

Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers.

Perez-Peña J, Corrales-Sánchez V, Amir E, Pandiella A, Ocana A.

Sci Rep. 2017 Dec 13;7(1):17530. doi: 10.1038/s41598-017-17836-7.

4.

Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer.

Alcaraz-Sanabria A, Nieto-Jiménez C, Corrales-Sánchez V, Serrano-Oviedo L, Andrés-Pretel F, Montero JC, Burgos M, Llopis J, Galán-Moya EM, Pandiella A, Ocaña A.

Mol Cancer Ther. 2017 Nov;16(11):2552-2562. doi: 10.1158/1535-7163.MCT-17-0223. Epub 2017 Aug 28.

5.

Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors.

Pérez-Peña J, Alcaraz-Sanabria A, Nieto-Jiménez C, Páez R, Corrales-Sánchez V, Serrano-Oviedo L, Wali VB, Patwardhan GA, Amir E, Győrffy B, Pandiella A, Ocaña A.

Oncotarget. 2017 Mar 28;8(13):21733-21740. doi: 10.18632/oncotarget.15562.

6.

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.

Nieto-Jiménez C, Alcaraz-Sanabria A, Pérez-Peña J, Corrales-Sánchez V, Serrano-Heras G, Galán-Moya EM, Serrano-Oviedo L, Montero JC, Burgos M, Llopis J, Pandiella A, Ocaña A.

Oncotarget. 2017 Mar 21;8(12):19478-19490. doi: 10.18632/oncotarget.14465.

7.

DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer.

Nieto-Jiménez C, Alcaraz-Sanabria A, Páez R, Pérez-Peña J, Corrales-Sánchez V, Pandiella A, Ocaña A.

Oncotarget. 2016 Jul 28;8(38):62834-62841. doi: 10.18632/oncotarget.10886. eCollection 2017 Sep 8.

8.

In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment.

Pérez-Peña J, Serrano-Heras G, Montero JC, Corrales-Sánchez V, Pandiella A, Ocaña A.

Mol Cancer Ther. 2016 Aug;15(8):1823-33. doi: 10.1158/1535-7163.MCT-16-0004. Epub 2016 Jun 2.

9.

Circulating DNA and Survival in Solid Tumors.

Ocaña A, Díez-González L, García-Olmo DC, Templeton AJ, Vera-Badillo F, José Escribano M, Serrano-Heras G, Corrales-Sánchez V, Seruga B, Andrés-Pretel F, Pandiella A, Amir E.

Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):399-406. doi: 10.1158/1055-9965.EPI-15-0893. Epub 2015 Nov 24. Review.

10.

Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses.

Ocana A, Ethier JL, Díez-González L, Corrales-Sánchez V, Srikanthan A, Gascón-Escribano MJ, Templeton AJ, Vera-Badillo F, Seruga B, Niraula S, Pandiella A, Amir E.

Oncotarget. 2015 Nov 24;6(37):39538-49. doi: 10.18632/oncotarget.5946. Review.

11.

Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors.

Serrano-Heras G, Cuenca-López MD, Montero JC, Corrales-Sanchez V, Morales JC, Núñez LE, Morís F, Pandiella A, Ocaña A.

Oncotarget. 2015 Oct 13;6(31):31272-83. doi: 10.18632/oncotarget.5211.

12.

Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer.

Cuenca-López MD, Serrano-Heras G, Montero JC, Corrales-Sánchez V, Gomez-Juarez M, Gascón-Escribano MJ, Morales JC, Voisin V, Núñez LE, Morís F, Bader GD, Pandiella A, Ocaña A.

Oncotarget. 2015 Sep 29;6(29):27923-37. doi: 10.18632/oncotarget.4736.

13.

Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis.

Ocana A, Vera-Badillo F, Al-Mubarak M, Templeton AJ, Corrales-Sanchez V, Diez-Gonzalez L, Cuenca-Lopez MD, Seruga B, Pandiella A, Amir E.

PLoS One. 2014 Apr 28;9(4):e95219. doi: 10.1371/journal.pone.0095219. eCollection 2014. Review.

Supplemental Content

Loading ...
Support Center